Squamous Cell Carcinoma of Head and Neck

Squamous Cell Carcinoma of the Head and Neck are cancers that are known collectively as head and neck cancers. Usually, they start in the squamous cells that line the mucosal surfaces of the head and neck (for example, those inside the mouth, throat, and voice box). Oral cavity and larynx cancers are generally associated with tobacco consumption, alcohol abuse or both, whereas pharynx cancers are increasingly attributed to infection with human papillomavirus (HPV), primarily HPV-16.

Showing 1–12 of 20 results

Filter our product list:
API
Antigen / Target
Therapeutic Areas
Therapeutic Indications
1
Classes of molecule​s
Isotypes
Expiry Date
CoA
Filters Sort results
Reset Apply

Product
Batch

Antigen
Molecular Class
Drug Brand
Product Concentration
CoA
Quantity per vial
Storage Temperature
Expiry Date
Price from
EGFR
Monoclonal Antibody
Erbitux®
5 mg/mL
2 mg
-80°C
2019.11
197,00 
view product
Max: 10
Min: 2
Step: 1
EGFR
Monoclonal Antibody
Erbitux®
5 mg/mL
2 mg
-80°C
2020.01
197,00 
view product
Max: 10
Min: 2
Step: 1
EGFR
Monoclonal Antibody
Erbitux®
5 mg/mL
2 mg
-80°C
2021.05
197,00 
view product
Max: 10
Min: 2
Step: 1
EGFR
Monoclonal Antibody
Erbitux®
5 mg/mL
5 mg
-80°C
2021.09
329,00 
view product
Max: 10
Min: 1
Step: 1
EGFR
Monoclonal Antibody
Erbitux®
5 mg/mL
2 mg
-80°C
2021.11
197,00 
view product
Max: 10
Min: 2
Step: 1
PD-1
Monoclonal Antibody
Opdivo®
10 mg/mL
2 mg
-80°C
2025.05
316,00 
view product
Max: 10
Min: 1
Step: 1
PD-1
Monoclonal Antibody
Opdivo®
10 mg/mL
2 mg
-80°C
2025.03
316,00 
view product
Max: 10
Min: 1
Step: 1
PD-1
Monoclonal Antibody
Opdivo®
10 mg/mL
2 mg
-80°C
2018.08
316,00 
view product
Max: 10
Min: 1
Step: 1
PD-1
Monoclonal Antibody
Opdivo®
10 mg/mL
2 mg
-80°C
2018.10
316,00 
view product
Max: 10
Min: 1
Step: 1
PD-1
Monoclonal Antibody
Opdivo®
10 mg/mL
2 mg
-80°C
2018.02
316,00 
view product
Max: 10
Min: 1
Step: 1
PD-1
Monoclonal Antibody
Opdivo®
10 mg/mL
2 mg
-80°C
2019.05
316,00 
view product
Max: 7
Min: 1
Step: 1
PD-1
Monoclonal Antibody
Opdivo®
10 mg/mL
2 mg
-80°C
2019.01
316,00 
view product
Max: 10
Min: 1
Step: 1
PD-1
Monoclonal Antibody
Opdivo®
10 mg/mL
2 mg
-80°C
2020.09
316,00 
view product
Max: 7
Min: 1
Step: 1
PD-1
Monoclonal Antibody
Opdivo®
10 mg/mL
2 mg
-80°C
2020.11
316,00 
view product
Max: 10
Min: 1
Step: 1
PD-1
Monoclonal Antibody
Opdivo®
10 mg/mL
2 mg
-80°C
2021.02
316,00 
view product
Max: 2
Min: 1
Step: 1
PD-1
Monoclonal Antibody
Keytruda®
25 mg/mL
2 mg
-80°C
2018.07
528,00 
view product
Max: 10
Min: 1
Step: 1
PD-1
Monoclonal Antibody
Keytruda®
25 mg/mL
2 mg
-80°C
2018.12
528,00 
view product
Max: 10
Min: 1
Step: 1
PD-1
Monoclonal Antibody
Keytruda®
25 mg/mL
2 mg
-80°C
2019.03
528,00 
view product
Max: 10
Min: 1
Step: 1
PD-1
Monoclonal Antibody
Keytruda®
25 mg/mL
2 mg
-80°C
2019.07
528,00 
view product
Max: 10
Min: 1
Step: 1
PD-1
Monoclonal Antibody
Keytruda®
25 mg/mL
2 mg
-80°C
2025.10
528,00 
view product
Max: 10
Min: 1
Step: 1

Not looking for Squamous Cell Carcinoma of Head and Neck?

Search our therapeutic molecules product database